Targeting CLEC9A delivers antigen to human CD141(+) DC for CD4(+) and CD8(+)T cell recognition

DC-based vaccines that initiate T cell responses are well tolerated and have demonstrated efficacy for tumor immunotherapy, with the potential to be combined with other therapies. Targeting vaccine antigens (Ag) directly to the DCs in vivo is more effective than cell-based therapies in mouse models...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Principais autores: Tullett, Kirsteen M., Leal Rojas, Ingrid M., Minoda, Yoshihito, Tan, Peck S., Zhang, Jian-Guo, Smith, Corey, Khanna, Rajiv, Shortman, Ken, Caminschi, Irina, Lahoud, Mireille H., Radford, Kristen J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2016
Assuntos:
Technical Advance
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5033826/
https://ncbi.nlm.nih.gov/pubmed/27699265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.87102
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados